272 related articles for article (PubMed ID: 30541488)
21. Clinical Features and Treatment Outcomes of 51 Patients with Chronic Myeloid Leukemia Treated with a Tyrosine Kinase Inhibitor at a Single Institution from 2002 to 2014.
Kawano N; Yoshida S; Kawano S; Kuriyama T; Yamashita K; Ochiai H; Shimoda K; Ishikawa F; Ueda A; Kikuchi I
J Clin Exp Hematop; 2016; 56(1):34-42. PubMed ID: 27334856
[TBL] [Abstract][Full Text] [Related]
22. Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients.
Hernández-Boluda JC; Pereira A; Pastor-Galán I; Alvarez-Larrán A; Savchuk A; Puerta JM; Sánchez-Pina JM; Collado R; Díaz-González A; Angona A; Sagüés M; García-Gutiérrez V; Boqué C; Osorio S; Vallansot R; Palomera L; Mendizábal A; Casado LF; Pérez-Encinas M; Pérez-López R; Ferrer-Marín F; Sánchez-Guijo F; García C; Heras NL; López-Lorenzo JL; Cervantes F; Steegmann JL;
Blood Cancer J; 2018 Dec; 8(10):91. PubMed ID: 30504932
[TBL] [Abstract][Full Text] [Related]
23. Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience.
Chamoun K; Kantarjian H; Atallah R; Gonzalez GN; Issa GC; Rios MB; Garcia-Manero G; Borthakur G; Ravandi F; Jain N; Daver N; Konopleva M; DiNardo CD; Kadia T; Pemmaraju N; Jabbour E; Cortes J
J Hematol Oncol; 2019 Jan; 12(1):1. PubMed ID: 30606227
[TBL] [Abstract][Full Text] [Related]
24. Response to Therapy, Treatment Intolerance and Tyrosine Kinase Inhibitor Cessation Eligibility in a Real-World Cohort of Chronic Myeloid Leukaemia Patients.
McMullan RR; McConville C; McMullin MF
Ulster Med J; 2019 May; 88(2):105-110. PubMed ID: 31061559
[TBL] [Abstract][Full Text] [Related]
25. Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
Kong JH; Winton EF; Heffner LT; Chen Z; Langston AA; Hill B; Arellano M; El-Rassi F; Kim A; Jillella A; Kota VK; Bodó I; Khoury HJ
Cancer; 2017 Jul; 123(13):2482-2488. PubMed ID: 28241101
[TBL] [Abstract][Full Text] [Related]
26. Subsequent attempt tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia; a single institute experience.
Ureshino H; Kamachi K; Nishioka A; Okamoto S; Katsuya H; Yoshimura M; Kubota Y; Ando T; Kimura S
Hematol Oncol; 2021 Oct; 39(4):549-557. PubMed ID: 34117654
[TBL] [Abstract][Full Text] [Related]
27. Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial).
Fujisawa S; Ueda Y; Usuki K; Kobayashi H; Kondo E; Doki N; Nakao T; Kanda Y; Kosugi N; Kosugi H; Kumagai T; Harada H; Shikami M; Maeda Y; Sakura T; Inokuchi K; Saito A; Nawa Y; Ogasawara M; Nishida J; Kondo T; Yoshida C; Kuroda H; Tabe Y; Maeda Y; Imajo K; Kojima K; Morita S; Komukai S; Kawaguchi A; Sakamoto J; Kimura S
Int J Clin Oncol; 2019 Apr; 24(4):445-453. PubMed ID: 30421023
[TBL] [Abstract][Full Text] [Related]
28. [Tyrosine kinase inhibitors discontinuation for chronic myeloid leukemia: a multicenter retrospective analysis in China].
Zhu XJ; You Y; Duan MH; Zhu Y; Liu BC; Chen SN; Du X
Zhonghua Xue Ye Xue Za Zhi; 2018 Dec; 39(12):994-997. PubMed ID: 30612400
[No Abstract] [Full Text] [Related]
29. Tyrosine kinase inhibitor discontinuation in the management of chronic myeloid leukemia: a critical review of the current practice.
Breccia M; Efficace F; Colafigli G; Scalzulli E; Di Prima A; Martelli M; Foà R
Expert Rev Hematol; 2020 Dec; 13(12):1311-1318. PubMed ID: 33205694
[No Abstract] [Full Text] [Related]
30. Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience.
Benjamini O; Kantarjian H; Rios MB; Jabbour E; O'Brien S; Jain P; Cardenas-Turanzas M; Faderl S; Garcia-Manero G; Ravandi F; Borthakur G; Quintas-Cardama A; Cortes J
Leuk Lymphoma; 2014 Dec; 55(12):2879-86. PubMed ID: 23927391
[TBL] [Abstract][Full Text] [Related]
31. Real-world therapeutic response and tyrosine kinase inhibitor discontinuation in chronic phase-chronic myeloid leukemia: data from the French observatory.
Saugues S; Lambert C; Daguenet E; Ansah HJ; Turhan A; Huguet F; Guerci-Bresler A; Tchirkov A; Hamroun D; Hermet E; Pereira B; Berger MG
Ann Hematol; 2022 Oct; 101(10):2241-2255. PubMed ID: 36040480
[TBL] [Abstract][Full Text] [Related]
32. Profiles of NK cell subsets are associated with successful tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia and changes following interferon treatment.
Kong J; Qin YZ; Zhao XS; Hou Y; Liu KY; Huang XJ; Jiang H
Ann Hematol; 2021 Oct; 100(10):2557-2566. PubMed ID: 34278524
[TBL] [Abstract][Full Text] [Related]
33. Real world treatment patterns in chronic myeloid leukemia patients newly initiated on tyrosine kinase inhibitors in an U.S. integrated healthcare system.
Rashid N; Koh HA; Lin KJ; Stwalley B; Felber E
J Oncol Pharm Pract; 2018 Jun; 24(4):253-263. PubMed ID: 29284347
[TBL] [Abstract][Full Text] [Related]
34. De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial.
Clark RE; Polydoros F; Apperley JF; Milojkovic D; Pocock C; Smith G; Byrne JL; de Lavallade H; O'Brien SG; Coffey T; Foroni L; Copland M
Lancet Haematol; 2017 Jul; 4(7):e310-e316. PubMed ID: 28566209
[TBL] [Abstract][Full Text] [Related]
35. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
Shiseki M; Yoshida C; Takezako N; Ohwada A; Kumagai T; Nishiwaki K; Horikoshi A; Fukuda T; Takano H; Kouzai Y; Tanaka J; Morita S; Sakamoto J; Sakamaki H; Inokuchi K
Int J Clin Oncol; 2017 Oct; 22(5):972-979. PubMed ID: 28550414
[TBL] [Abstract][Full Text] [Related]
36. Budget Impact of Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia With Sustained Deep Molecular Response.
Astrugue C; Bénard A; Bosco-Levy P; Dulucq S; Rouyer M; Lassalle R; Hayes N; Mahon FX
Value Health; 2021 May; 24(5):683-690. PubMed ID: 33933237
[TBL] [Abstract][Full Text] [Related]
37. Assessment of molecular response to tyrosine kinase inhibitors in Tunisian Patients with Chronic Myeloid Leukemia.
Frikha R; Kassar O; Elloumi M; Kamoun H
J Oncol Pharm Pract; 2022 Dec; 28(8):1826-1831. PubMed ID: 34846219
[TBL] [Abstract][Full Text] [Related]
38. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.
Rousselot P; Charbonnier A; Cony-Makhoul P; Agape P; Nicolini FE; Varet B; Gardembas M; Etienne G; Réa D; Roy L; Escoffre-Barbe M; Guerci-Bresler A; Tulliez M; Prost S; Spentchian M; Cayuela JM; Reiffers J; Chomel JC; Turhan A; Guilhot J; Guilhot F; Mahon FX
J Clin Oncol; 2014 Feb; 32(5):424-30. PubMed ID: 24323036
[TBL] [Abstract][Full Text] [Related]
39. How I manage relapse of chronic myeloid leukaemia after stopping tyrosine kinase inhibitor therapy.
Rea D; Mahon FX
Br J Haematol; 2018 Jan; 180(1):24-32. PubMed ID: 29048128
[TBL] [Abstract][Full Text] [Related]
40. [Tyrosine kinase inhibitor therapy discontinuation for chronic myelogenous leukemia to achieve clinical cure: current status and future perspectives].
Kumagai T
Rinsho Ketsueki; 2018; 59(10):2094-2103. PubMed ID: 30305514
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
